OSUR vs VCYT
OSUR: OrasuRe is a diagnostic company specializing in rapid point-of-care and self-test solutions for infectious diseases and rare conditions, with recent expansion into sickle cell screening through the BioMedomics acquisition. VCYT: Veracyte is a genomic diagnostics company transforming cancer care with advanced, high-value testing platforms across the patient journey from diagnosis to monitoring.
Side-by-side fundamentals
| Metric | OSUR | VCYT | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $4.00 | $46.27 | |
| Market cap as of 2026-08-11 | $276M | $3.7B | |
| P/E as of 2026-08-11 | n/a | 32.41 | |
| PEG as of 2026-08-11 | -6.92 | 0.10 | OSUR lower |
| Net margin as of 2026-08-11 | -66.4% | +20.4% | VCYT higher |
| Gross margin as of 2026-08-11 | +42.5% | +71.7% | VCYT higher |
| Operating margin as of 2026-08-11 | -68.6% | +19.6% | VCYT higher |
| ROE as of 2026-08-11 | -21.5% | +8.6% | VCYT higher |
| ROA as of 2026-08-11 | -18.2% | +8.0% | VCYT higher |
| Debt / equity as of 2026-08-11 | 0.00 | 0.00 | VCYT lower |
| Revenue growth (YoY) as of 2026-08-11 | -30.1% | +17.3% | VCYT higher |
| Revenue CAGR (3y) SEC XBRL | -33.3% | +20.4% | VCYT higher |
| Beta as of 2026-08-11 | 1.07 | 1.98 | |
| 1-year return as of 2026-08-10 close | +43.9% | +69.1% | VCYT higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.